Lung Cancer Research Review, Issue 58

In this issue:

Bevacizumab biosimilar for nonsquamous NSCLC
Neoantigen vaccination for NSCLC with EGFR mutation
Impact of race/ethnicity on response to PD1/PD-L1 inhibitors in advanced NSCLC
Pembrolizumab + ipilimumab for metastatic NSCLC with PD-L1 TPS ≥50%
Pembrolizumab for metastatic NSCLC with PD-L1 TPS ≥50%
Veliparib-carboplatin-etoposide in treatment-naïve extensive-stage SCLC
Pepinemab + avelumab in advanced NSCLC
Anti-PD1 antibodies in PD-L1-positive recurrent/metastatic NSCLC
SABR vs. surgery in older stage I lung cancer patients
Resection after neoadjuvant chemoimmunotherapy in stage IIIA NSCLC

Please login below to download this issue (PDF)